The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Clinical trials investigating treatment approaches for FLT3-mutated and IDH-mutated AML patients
Peter Valk, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, gives an overview of two ongoing Phase III HOVON clinical trials investigating novel treatment approaches for patients with acute myeloid leukemia (AML). Dr Valk first discusses the HOVON 156 AML trial (NCT04027309), which is investigating the effect of gilteritinib versus midostaurin in patients with FLT3-mutated AML. Dr Valk then mentions the HOVON 150 AML trial (NCT03839771), which is investigating the effect of IDH1 and IDH2 inhibitors in IDH-mutated patients. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
